Myriad Genetics, Quest Diagnostics diagnostic news

Myriad and Quest reached a settlement to dismiss litigation related to Myriad’s breast cancer 1 early onset (BRCA1) and BRCA2 genes. Myriad promised not to sue Quest under the patents asserted in the litigation. In October 2013, Quest filed the complaint in the U.S. District Court for the Central District of California seeking declaration that Myriad has no rights against Quest regarding the patents. The case was transferred to the U.S. Judicial Panel on Multidistrict Litigation the following month. Quest markets its BRCAvantage sequencing services to help identify genetic risk for breast and ovarian cancer based on BRCA1 and BRCA2 mutations. ...